Autophagy modulation in cancer therapy: Challenges coexist with opportunities

被引:8
作者
Wu, Yongya [1 ]
Wang, Aoxue [1 ]
Feng, Guotai [1 ]
Pan, Xiaoli [1 ]
Shuai, Wen [1 ]
Yang, Panpan [1 ]
Zhang, Jing [1 ]
Ouyang, Liang [1 ]
Luo, Yi [1 ,2 ]
Wang, Guan [1 ,2 ]
机构
[1] Sichuan Univ, Orthoped Res Inst, Dept Biotherapy,Canc Ctr,Innovat Ctr Nursing Res, Dept Orthoped,West China Hosp,West China Sch Nursi, Chengdu 610041, Peoples R China
[2] Sichuan Univ, Dept Orthoped, Innovat Ctr Nursing Res Nursing,Key Lab Sichuan Pr, State Key Lab Biotherapy,Orthoped Res Inst West Ch, Chengdu 610041, Peoples R China
基金
中国国家自然科学基金;
关键词
Autophagy; Signaling pathways; Drug targets; Small molecule modulators; Malignancy treatment; NEGATIVE BREAST-CANCER; PROTEIN-KINASE AMPK; PHOSPHATIDYLINOSITOL; 3-KINASE; MAMMALIAN TARGET; CELL-DEATH; PRECLINICAL PHARMACOLOGY; ANTITUMOR-ACTIVITY; DUAL INHIBITION; MTOR INHIBITOR; IN-VITRO;
D O I
10.1016/j.ejmech.2024.116688
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Autophagy, a crucial intracellular degradation process facilitated by lysosomes, plays a pivotal role in maintaining cellular homeostasis. The elucidation of autophagy key genes and signaling pathways has significantly advanced our understanding of this process and has led to the exploration of autophagy as a promising therapeutic approach. This review comprehensively assesses the latest developments in small molecule modulators targeting autophagy. Moreover, the review delves into the most recent strategies for drug discovery, specifically focusing on selective agents that exploit autophagosomes and lysosomes for targeted protein degradation. Additionally, this article highlights the prevailing challenges and outlines potential future advancements in the field. By amalgamating the cutting-edge knowledge in the field, we aim to offer valuable insights and references for the anti-cancer drug development of autophagy-targeted therapies, thus contributing to the advancement of novel therapeutic interventions.
引用
收藏
页数:27
相关论文
共 178 条
[41]   Mechanism of interaction between autophagy and apoptosis in cancer [J].
Das, Shreya ;
Shukla, Nidhi ;
Singh, Shashi Shekhar ;
Kushwaha, Sapana ;
Shrivastava, Richa .
APOPTOSIS, 2021, 26 (9-10) :512-533
[42]   Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background [J].
Davies, Barry R. ;
Greenwood, Hannah ;
Dudley, Phillippa ;
Crafter, Claire ;
Yu, De-Hua ;
Zhang, Jingchuan ;
Li, Jing ;
Gao, Beirong ;
Ji, Qunsheng ;
Maynard, Juliana ;
Ricketts, Sally-Ann ;
Cross, Darren ;
Cosulich, Sabina ;
Chresta, Christine C. ;
Page, Ken ;
Yates, James ;
Lane, Clare ;
Watson, Rebecca ;
Luke, Richard ;
Ogilvie, Donald ;
Pass, Martin .
MOLECULAR CANCER THERAPEUTICS, 2012, 11 (04) :873-887
[43]   Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors [J].
Davis, S. Lindsey ;
Ionkina, Anastasia A. ;
Bagby, Stacey M. ;
Orth, James D. ;
Gittleman, Brian ;
Marcus, Joshua M. ;
Lam, Elaine T. ;
Corr, Bradley R. ;
O'Bryant, Cindy L. ;
Glode, Ashley E. ;
Tan, Aik-Choon ;
Kim, Jihye ;
Tentler, John J. ;
Capasso, Anna ;
Lopez, Kyrie L. ;
Gustafson, Daniel L. ;
Messersmith, Wells A. ;
Leong, Stephen ;
Eckhardt, S. Gail ;
Pitts, Todd M. ;
Diamond, Jennifer R. .
CLINICAL CANCER RESEARCH, 2020, 26 (17) :4633-4642
[44]   ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation [J].
de Jong, Petrus R. ;
Taniguchi, Koji ;
Harris, Alexandra R. ;
Bertin, Samuel ;
Takahashi, Naoki ;
Duong, Jen ;
Campos, Alejandro D. ;
Powis, Garth ;
Corr, Maripat ;
Karin, Michael ;
Raz, Eyal .
NATURE COMMUNICATIONS, 2016, 7
[45]   SIRT1 attenuates sepsis-induced acute kidney injury via Beclin1 deacetylation-mediated autophagy activation [J].
Deng, Zhiya ;
Sun, Maomao ;
Wu, Jie ;
Fang, Haihong ;
Cai, Shumin ;
An, Sheng ;
Huang, Qiaobing ;
Chen, Zhenfeng ;
Wu, Chenglun ;
Zhou, Ziwei ;
Hu, Haoran ;
Zeng, Zhenhua .
CELL DEATH & DISEASE, 2021, 12 (02)
[46]   Emerging degrader technologies engaging lysosomal pathways [J].
Ding, Yu ;
Xing, Dong ;
Fei, Yiyan ;
Lu, Boxun .
CHEMICAL SOCIETY REVIEWS, 2022, 51 (21) :8832-8876
[47]   Emerging New Concepts of Degrader Technologies [J].
Ding, Yu ;
Fei, Yiyan ;
Lu, Boxun .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2020, 41 (07) :464-474
[48]   Modulating Mitophagy in Mitochondrial Disease [J].
Dombi, Eszter ;
Mortiboys, Heather ;
Poulton, Joanna .
CURRENT MEDICINAL CHEMISTRY, 2018, 25 (40) :5597-5612
[49]   Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design [J].
Donald, Alastair ;
McHardy, Tatiana ;
Rowlands, Martin G. ;
Hunter, Lisa-Jane K. ;
Davies, Thomas G. ;
Berdini, Valerio ;
Boyle, Robert G. ;
Aherne, G. Wynne ;
Garrett, Michelle D. ;
Collins, Ian .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (10) :2289-2292
[50]   Ispinesib as an Effective Warhead for the Design of Autophagosome-Tethering Chimeras: Discovery of Potent Degraders of Nicotinamide Phosphoribosyltransferase (NAMPT) [J].
Dong, Guoqiang ;
Wu, Ying ;
Cheng, Junfei ;
Chen, Long ;
Liu, Rui ;
Ding, Yu ;
Wu, Shanchao ;
Ma, Junhui ;
Sheng, Chunquan .
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (11) :7619-7628